Biogenerics:
Challenges and Promise takes an insightful look
at the burgeoning biogenerics industry and helps
to clarify the complicated regulations that currently
govern biogeneric development in both the US and
Europe. It provides vital information and analysis
concerning the progress that the biogeneric industry
continues to make, and the stumbling blocks that
threaten the future vitality of this fledgling industry.
It also pinpoints therapeutic areas that are ripe
for biogeneric competition and highlights the progress
of trailblazing companies active in both Europe
and the US.
This
report primarily focuses on how the generics industry
will be shaped by the global healthcare market and
regulatory developments over the next five years.
The international biogenerics market faces a multitude
of challenges. Biogenerics: Challenges and Promise
will assess those challenges and analyze the potential
for maximizing the myriad opportunities available
in this competitive and dynamic industry. The report
also appraises and compares current and emerging
biogeneric products and identifies those with the
most potential for growth.
Key
questions answered in this report:
-
Who
are the major players in the biogenerics arena
and what kind of impact are they making on the
industry?
-
What
obstacles stand in the way of a smooth transition
from biopharmaceutical manufacture to biogenerics?
-
How
has the lack of a clear framework impeded the
industry's progress in producing and distributing
biogeneric drugs? And how will these issues be
resolved?
-
What
specific hurdles must biogeneric manufacturers
maneuver in order to get their products on the
market?
-
Thorough
analysis of the drivers of and restraints on the
biogenerics market
-
Detailed
information and analysis concerning groundbreaking
biogeneric regulation in the US and Europe.
-
Identification
of key biopharmaceuticals at risk for biogeneric
competition
-
In-depth
profiles of leading pharmaceutical companies involved
in the biogenerics industry
-
Analytical
discussions which integrate regulatory issues
with market activity and company activity
|
